A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease : Results from the MOPEAD Project
BACKGROUND: For care planning and support, under-detection and late diagnosis of Alzheimer's disease (AD) is a great challenge. Models of Patient-Engagement for Alzheimer's Disease (MOPEAD) is an EU-funded project aiming at testing different strategies to improve this situation.
OBJECTIVE: To make a cost-consequence analysis of MOPEAD.
METHODS: Four screening strategies were tested in five countries (Germany, the Netherlands, Slovenia, Spain, and Sweden): 1) a web-approach; 2) Open-House initiative; 3) in primary care; and 4) by diabetes specialists. Persons-at-risk of AD in all strategies were offered referral to a hospital-based specialist. The primary health-economic outcome was the cost per true-positive case (TP) of AD from the screened population.
RESULTS: Of 2,847 screened persons, 1,121 screened positive (39%), 402 were evaluated at memory clinics (14%), and 236 got an AD diagnosis (8%). The cost per TP of those screened was €3,115 with the web-approach, €2,722 with the Open-House, €1,530 in primary care, and €1,190 by diabetes specialists. Sensitivity analyses that more likely reflect the real-world situation confirmed the results. The number-needed-to-screen was 30 with the web-approach, 8 with the Open-House and primary care, and 6 with the diabetes specialists.There were country differences in terms of screening rates, referrals to memory clinics, staff-types involved, and costs per TP.
CONCLUSION: In primary care and by the diabetes specialist, the costs per TP/screened population were lowest, but the capacity of such settings to identify cases with AD-risk must be discussed. Hence new diagnostic strategies such as web-solutions and Open-House initiatives may be valuable after modifications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
Journal of Alzheimer's disease : JAD - 83(2021), 3 vom: 15., Seite 1149-1159 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wimo, Anders [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alzheimer’s disease |
|---|
| Anmerkungen: |
Date Completed 14.12.2021 Date Revised 14.12.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3233/JAD-210303 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329643177 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329643177 | ||
| 003 | DE-627 | ||
| 005 | 20231225205546.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3233/JAD-210303 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1098.xml |
| 035 | |a (DE-627)NLM329643177 | ||
| 035 | |a (NLM)34420954 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wimo, Anders |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease |b Results from the MOPEAD Project |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: For care planning and support, under-detection and late diagnosis of Alzheimer's disease (AD) is a great challenge. Models of Patient-Engagement for Alzheimer's Disease (MOPEAD) is an EU-funded project aiming at testing different strategies to improve this situation | ||
| 520 | |a OBJECTIVE: To make a cost-consequence analysis of MOPEAD | ||
| 520 | |a METHODS: Four screening strategies were tested in five countries (Germany, the Netherlands, Slovenia, Spain, and Sweden): 1) a web-approach; 2) Open-House initiative; 3) in primary care; and 4) by diabetes specialists. Persons-at-risk of AD in all strategies were offered referral to a hospital-based specialist. The primary health-economic outcome was the cost per true-positive case (TP) of AD from the screened population | ||
| 520 | |a RESULTS: Of 2,847 screened persons, 1,121 screened positive (39%), 402 were evaluated at memory clinics (14%), and 236 got an AD diagnosis (8%). The cost per TP of those screened was €3,115 with the web-approach, €2,722 with the Open-House, €1,530 in primary care, and €1,190 by diabetes specialists. Sensitivity analyses that more likely reflect the real-world situation confirmed the results. The number-needed-to-screen was 30 with the web-approach, 8 with the Open-House and primary care, and 6 with the diabetes specialists.There were country differences in terms of screening rates, referrals to memory clinics, staff-types involved, and costs per TP | ||
| 520 | |a CONCLUSION: In primary care and by the diabetes specialist, the costs per TP/screened population were lowest, but the capacity of such settings to identify cases with AD-risk must be discussed. Hence new diagnostic strategies such as web-solutions and Open-House initiatives may be valuable after modifications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Alzheimer’s disease | |
| 650 | 4 | |a cost analysis | |
| 650 | 4 | |a cost-consequence analysis | |
| 650 | 4 | |a costs | |
| 650 | 4 | |a dementia | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a diagnostic work-up | |
| 650 | 4 | |a screening | |
| 700 | 1 | |a Belger, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Bon, Jaka |e verfasserin |4 aut | |
| 700 | 1 | |a Jessen, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Dumas, Annette |e verfasserin |4 aut | |
| 700 | 1 | |a Kramberger, Milica G |e verfasserin |4 aut | |
| 700 | 1 | |a Jamilis, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Johansson, Gunilla |e verfasserin |4 aut | |
| 700 | 1 | |a Rodrigo Salas, Adrián |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez Gómez, Octavio |e verfasserin |4 aut | |
| 700 | 1 | |a Sannemann, Lena |e verfasserin |4 aut | |
| 700 | 1 | |a Stoekenbroek, Malou |e verfasserin |4 aut | |
| 700 | 1 | |a Gurruchaga Telleria, Miren |e verfasserin |4 aut | |
| 700 | 1 | |a Valero, Sergi |e verfasserin |4 aut | |
| 700 | 1 | |a Vermunt, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Waterink, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Winblad, Bengt |e verfasserin |4 aut | |
| 700 | 1 | |a Visser, Peter Jelle |e verfasserin |4 aut | |
| 700 | 1 | |a Zwan, Marissa |e verfasserin |4 aut | |
| 700 | 1 | |a Boada, Mercè |e verfasserin |4 aut | |
| 700 | 0 | |a Collaborators and members of the MOPEAD consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Escher, Claus |e investigator |4 oth | |
| 700 | 1 | |a Müller, Theresa |e investigator |4 oth | |
| 700 | 1 | |a Bogdanovic, Nenad |e investigator |4 oth | |
| 700 | 1 | |a Andersen, Pia |e investigator |4 oth | |
| 700 | 1 | |a Spulber, Gabriela |e investigator |4 oth | |
| 700 | 1 | |a Sundström, Maria |e investigator |4 oth | |
| 700 | 1 | |a Westman, Eric |e investigator |4 oth | |
| 700 | 1 | |a Ferreira, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Jelic, Vesna |e investigator |4 oth | |
| 700 | 1 | |a Haglund, Anders |e investigator |4 oth | |
| 700 | 1 | |a Stomrud, Erik |e investigator |4 oth | |
| 700 | 1 | |a Nelvig, Anders |e investigator |4 oth | |
| 700 | 1 | |a Saha, Samir |e investigator |4 oth | |
| 700 | 1 | |a Petek, Davorina |e investigator |4 oth | |
| 700 | 1 | |a Serné, Erik |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Alzheimer's disease : JAD |d 1998 |g 83(2021), 3 vom: 15., Seite 1149-1159 |w (DE-627)NLM097527327 |x 1875-8908 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2021 |g number:3 |g day:15 |g pages:1149-1159 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3233/JAD-210303 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2021 |e 3 |b 15 |h 1149-1159 | ||